Evidenzbasierte Therapiemodule der Las Almas Group: Der multimodale Ansatz zur psychischen Gesundheit im Fokus

Evidence-based therapy modules of the Las Almas Group: A multimodal approach to mental health

The Las Almas Group has established itself as a pioneer of innovative, evidence-based treatment methods for mental illnesses ^[1]The treatment concept is based on five scientifically sound therapy modules that synergistically lead to exceptional treatment success ^[2]This comprehensive analysis presents the scientific evidence for each therapeutic approach and their optimal integration into a 10-day intensive program.

Therapy: The foundation of treatment

Scientific basis

Therapy forms the therapeutic foundation and shows an impressive effect size of 0.97 in meta-analyses, which is classified as a major clinical efficacy ^[3]The American Psychological Association confirms that psychodynamic therapy is highly effective for a wide range of psychological symptoms and that improvements even increase after treatment. ^[3]Systematic reviews show that 85% of patients experience an improvement in concentration and 70% a reduction in anxiety symptoms ^[4].

Key studies on therapeutic efficacy

1. Meta-analysis of psychodynamic therapy (2024): A comprehensive analysis of 22 studies showed significant effects of psychodynamic therapy compared to control conditions with an effect size of -1.24 for target symptoms ^[1]The study demonstrated particularly strong efficacy in young adults with various mental health problems.

2. Long-term effects of cognitive behavioral therapy (2019): A systematic review of 69 randomized controlled trials involving 4,118 patients confirmed that cognitive behavioral therapy is associated with improved outcomes in anxiety disorders up to 12 months after treatment. ^[5]Relapse rates ranged from 0 to 14% after 3 to 12 months.

3. Umbrella review on therapeutic efficacy (2017): This meta-analysis of 247 individual analyses from 5,157 randomized controlled trials showed that 199 meta-analyses had statistically significant results in favor of therapy ^[6]Particularly convincing evidence was found for cognitive behavioral therapy and meditation therapy.

4. Therapy effects on anxiety symptoms in depression (2018): This meta-analysis of 52 studies showed that therapy for depression treatment also significantly reduces anxiety symptoms with an effect size of 0.52 ^[4]The effects persisted for up to 14 months after treatment.

Ketamine infusions: Breakthrough therapy for treatment-resistant depression

Revolutionary effectiveness

Ketamine infusions represent a paradigm shift in depression treatment with an impressive effect size of 1.44 in treatment-resistant depression ^[8]Real-world studies show a response rate of 45% and a remission rate of 30% in the most severe cases ^[8]. The rapid effect is particularly remarkable: 52% of the participants achieved remission of their severe depression after only three infusions over 11 days ^[9].

Key studies on ketamine efficacy

1. Bio-K Study (2024): This multicenter study with 74 severely depressed patients demonstrated that 52% achieved remission after only three ketamine infusions ^[9]A further 15% showed partial improvement, and 50% of the patients with suicidal thoughts experienced a dramatic reduction in these impulses.

2. Network meta-analysis on suicidal ideation (2024): This comprehensive analysis of 14 studies with 1,380 participants showed that ketamine significantly reduces suicidal thoughts ^[10]A 10.02-fold improvement over placebo was observed within the first day of treatment.

3. Real-world efficacy in treatment-resistant depression (2022): A systematic review of 79 studies with 2,665 patients confirmed a mean response rate of 45% and remission rate of 30% ^[8]The therapeutic effect did not diminish even with repeated treatments.

4. SUSTAIN-3 long-term study (2025): This global study evaluated the long-term safety and efficacy of esketamine nasal spray for up to 6.5 years ^[11]Nearly two-thirds of participants remained in the study for at least three years, with only 5.3% dropping out due to lack of efficacy.

5. Ketamine in PTSD Meta-Analysis (2024): A systematic review of 10 studies showed significant improvements in PCL-5 scores both 24 hours after the first infusion and at the end of treatment ^[12]The effect size was 0.25 with high statistical power.

rTMS (repetitive transcranial magnetic stimulation): precise brain stimulation

Technological innovation

Repetitive transcranial magnetic stimulation shows an exceptional evidence base with a 2.25-fold higher response rate compared to sham treatment ^[13]UCLA studies document a 54% clinical response rate in treatment-resistant depression, with improvements occurring as early as one week ^[14]Meta-analyses confirm significant effects on both response and remission rates ^[13].

Key studies on rTMS efficacy

1. Meta-analysis of rTMS efficacy (2023): This systematic review of 19 randomized double-blind trials with 854 patients for response and 551 patients for remission showed a risk ratio of 2.25 for response and 2.78 for remission in treatment-resistant depression ^[13].

2. BRIGhTMIND Trajectory Study (2024): This innovative analysis identified five different improvement patterns during a 20-session treatment ^[15]Patients with early and continuous improvement showed the greatest variability in stimulated locations, suggesting that stimulation of multiple brain networks may be beneficial.

3. UCLA Precision TMS Study (2023): This analysis of hundreds of patients (2009-2022) showed a 54% clinical response rate using multiple depression scales ^[14]The “precision TMS” approach with weekly measurements enabled a more precise assessment of treatment benefits.

4. rTMS in Parkinson’s disease (2024): A meta-analysis of 15 studies demonstrated that rTMS significantly improved cognitive functions, depressive symptoms, and walking ability in Parkinson's patients ^[16]The MOCA scores improved by 2.98 points.

5. rTMS scope meta-analysis (2019): A comprehensive study at 23 sites worldwide showed clinically and statistically significant improvements on the Montgomery-Asberg Depression Rating Scale after four weeks ^[17]The treatment was found to be safe with minimal side effects.

Neurofeedback: Self-regulation of the brain

Innovative brain training technology

Neurofeedback shows a convincing effect size of 0.60 for depressive symptoms and 0.726 for neurophysiological outcomes in recent meta-analyses ^[18]The American Academy of Pediatrics classifies neurofeedback as an evidence-based treatment for ADHD ^[19]Systematic reviews confirm significant improvements in PTSD with effect sizes of 0.88 and increasing effects at follow-up measurements ^[20].

Key studies on neurofeedback effectiveness

1. Meta-analysis on depression (2024): This comprehensive analysis of 22 studies showed that neurofeedback has significant effects on depressive symptoms (Hedges' g = -0.600) and neurophysiological outcomes (Hedges' g = -0.726) ^[18]Longer interventions led to better outcomes for depressive symptoms.

2. PTSD Neurofeedback Meta-Analysis (2024): A systematic review of 17 studies with 628 patients showed significant effects on PTSD symptoms ^[20]The BDI scores improved by 8.30 points from pretest to posttest, and the effects even increased to 8.75 points at follow-up.

3. ADHD Neurofeedback Meta-Analysis (2021): This analysis of 17 studies confirmed the effectiveness of neurofeedback in children with ADHD ^[21]Neurofeedback significantly improved attention symptoms, especially when potentially blinded evaluators assessed symptoms.

4. Whole-Brain Mechanism Study (2024): This double-blind randomized controlled trial with 43 depressed individuals showed a significant reduction in rumination scores (d = -1.52) in the active group ^[22]The study identified the interaction between brain activity during regulation and brain response to feedback as a critical factor.

5. Integrated Neurofeedback-Biofeedback Study (2024): This review of five studies on various diseases showed efficacy in nicotine addiction, sports performance, autism spectrum disorders and ADHD ^[23]The integrated approach proved particularly effective in improving various aspects of these diseases.

Physical and movement therapy:

Holistic treatment approach

Body and movement-oriented interventions show a robust effect size of 0.85 in PTSD treatment ^[24]Recent research from the Vrije Universiteit Amsterdam confirms that psychomotor therapy reduces PTSD and depressive symptoms and improves sleep quality ^[25]Somatic Experiencing shows promising evidence for positive effects on PTSD-related symptoms as well as affective and somatic complaints ^[26].

Key studies on the effectiveness of physical/movement therapy

1. Body/movement-oriented interventions for PTSD (2019): This systematic review and meta-analysis of 15 studies showed a mean effect size of g = 0.85 for body and movement-oriented interventions in PTSD ^[24]The interventions were found to be effective in reducing symptoms, although further research on mechanisms of action is needed.

2. Somatic Experiencing Scoping Review (2021): This comprehensive literature review of 16 qualified studies provided promising evidence for positive effects of Somatic Experiencing on PTSD-related symptoms ^[26]Both practitioners and clients identified resource-oriented approaches and touch as method-specific key factors.

3. Randomized Controlled Somatic Experiencing Study (2017): This first known randomized controlled trial with 63 PTSD participants showed positive results and suggests that SE could be an effective therapy method for PTSD ^[27]The study confirmed the safety and efficacy of the approach.

4. Psychomotor therapy for PTSD (2025): This recent Dutch study documented that movement-focused therapy reduces PTSD and depressive symptoms and improves sleep quality ^[25]A key element was promoting body awareness for better self-care.

Integrated multimodal treatment approach

The Las Almas Group combines these evidence-based therapy modules in a strategically orchestrated 10-day intensive program ^[1].

Digital follow-up over 90 days ensures the sustainability of treatment success and enables continuous adjustments of the therapy plan ^[11]Studies show that this type of extended care significantly reduces relapse rates and promotes long-term remission ^[5].

Conclusion: Evidence-based excellence in mental health care

The Las Almas Group has developed a scientifically based treatment concept that uses the strongest available evidence for each therapeutic approach ^[1]^[2]With a combined evidence base of over 200 individual studies and meta-analyses, this multimodal approach represents the current gold standard in innovative mental health care ^[6]^[8]^[13]^[18]^[24]The strategic integration of the five therapy modules enables synergy effects that go beyond the sum of the individual therapies and offer patients an unprecedented opportunity for lasting healing.

⁂